+1,192.7%
MRVL vs GSK
+182.7%
+1,010.0%
-91.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.7% | -0.4% | -4.3% | -4.5% |
| 7D | +11.0% | +0.2% | +10.8% | +10.9% |
| 30D | -36.1% | +5.4% | -41.5% | -37.7% |
| 3M | -29.4% | +0.9% | -30.3% | -30.3% |
| 6M | -11.9% | +0.7% | -12.6% | -14.1% |
| YTD | +84.8% | +5.6% | +79.2% | +75.5% |
| 1Y | +79.4% | +8.5% | +70.9% | +68.4% |
| 3Y | +195.7% | +63.8% | +131.9% | +119.0% |
| 5Y | +117.2% | +42.4% | +74.7% | +68.7% |
| 10Y | +1,193.7% | +102.3% | +1,091.4% | +727.9% |
| All | +1,192.7% | +182.7% | +1,010.0% | +506.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling